Friday, May 1, 2026

Herpes and the Brain: Could a Common STI Be Fueling the Dementia Crisis?

A study reveals men with genital herpes (HSV-2) face over double the dementia risk, highlighting the need for awareness and research.

Apple vs Epic Games: Will the Supreme Court End the In-App Payment Battle in 2024?

Apple appeals to the Supreme Court over in-app payment fees following a contempt ruling, while Google reduces its app payment fees.

Qatar to Host 2025 FIFA U-17 World Cup with 48 Teams in November

The 2025 FIFA U-17 World Cup in Qatar will feature 48 teams from November 3 to 27, marking significant changes in the tournament format.

Jung Eun Kim

Author's Latest

Wontek’s V-Laser Approved for Versatile Treatments in Vietnam: A Game-Changer for Aesthetic Clinics

Wontech secures medical device approval for its V-Laser in Vietnam, enhancing its product lineup and market presence in medical aesthetics.

Medipost’s Cartistem: Achieving 3000 Knee Cartilage Restoration Surgeries – A Game Changer for Osteoarthritis Treatment

Medipost's Cartistem therapy reaches 3,000 procedures for cartilage restoration, proving its safety and efficacy for knee osteoarthritis.

Why Centrum Multivitamins Are Backed by 32 Clinical Studies: A Deep Dive into Their Proven Benefits

Centrum multivitamins stand out for their extensive research backing, showing benefits in cancer risk reduction and cognitive function.

Celltrion’s Remsima Surpasses 1 Trillion KRW in Sales for 2nd Consecutive Year: What’s Driving Its Success?

Celltrion's Remsima treatment surpasses 1 trillion KRW in sales, driven by European market growth and new liquid formulation.

Samsung Biologics Partners with CEPI: A Game-Changer for Global Vaccine Production

Samsung Biologics partners with CEPI to enhance vaccine production for pandemics, aiming for rapid global supply and health security.

HM15275 Clinical Trials: What You Need to Know About This Groundbreaking Obesity Treatment

Hanmi Pharmaceutical's HM15275 enters Phase 2 trial, aiming to revolutionize obesity treatment and diabetes management by 2030.

Celltrion’s Remsima SC: The Leading Autoimmune Drug with 68% Market Share in Europe

Celltrion's treatments for autoimmune diseases and cancer maintain strong market positions in Europe, bolstered by stable prescriptions and new products.

Pneumonia Death Rates in South Korea: Why Vaccination is Crucial for High-Risk Groups

Pneumonia is South Korea's third leading cause of death; prevention is crucial, especially for high-risk groups after influenza.

Samsung Bioepis Expands SB15 Eylea Rival: Licensing Pact Targets Global Markets as Original Drug Hits $10.5B Sales

Samsung Bioepis has secured a licensing deal for its ophthalmic treatment SB15, expanding access in international markets outside the US and Canada.

How Celltrion is Tackling U.S. Tariff Risks with New Production Facility in 2026

Celltrion addresses tariff risks by acquiring a U.S. facility, ensuring product supply and implementing strategies to mitigate uncertainties.

Why a High-Concentration Albumin Product Is Expanding Nationwide After 13 Straight Sellouts

Daewon Pharmaceutical expands offline distribution of Albumin King to major department stores across Korea, boosting consumer access and sales.

Revolutionary mRNA Cancer Treatment Shows 49% Survival Improvement: What You Need to Know

A study shows mRNA-based cancer treatments significantly improve survival rates, marking a breakthrough in precision therapy for melanoma.

Eli Lilly vs. Novo Nordisk: A $1.2 Billion Bet Reveals Two Very Different Futures for Obesity Drugs

Eli Lilly and Novo Nordisk are pursuing different strategies in the obesity treatment market, focusing on expansion versus core strengths.

Why Ebola Now? SK Bioscience Joins a $30 Million Global Push to Rethink Ebola Vaccine Production

SK Bioscience secures funding to enhance Ebola vaccine production, improving yield and stability for better accessibility amid outbreaks.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.